<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541108</url>
  </required_header>
  <id_info>
    <org_study_id>PBI-MST-01</org_study_id>
    <nct_id>NCT04541108</nct_id>
  </id_info>
  <brief_title>Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies</brief_title>
  <official_title>A Phase 0 Master Protocol Using the CIVOÂ® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presage Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Presage Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized&#xD;
      pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when&#xD;
      administered intratumorally in microdose quantities via the CIVO device in patients with&#xD;
      surface accessible solid tumors for which there is a scheduled surgical intervention. CIVO&#xD;
      stands for Comparative In Vivo Oncology. Multiple substudies will include specified&#xD;
      investigational agents and combinations to be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CIVO is a research tool composed of a hand-held single-use sterile injector coupled with&#xD;
      fluorescent tracking microspheres called CIVO GLO that mark the sites of drug microdose&#xD;
      injection, enabling rapid assessment of multiple oncology drugs or drug combinations&#xD;
      simultaneously within a patient's tumor. Tumor responses to cancer treatments are highly&#xD;
      context-specific and often involve complex interactions between the anti-cancer therapy,&#xD;
      genetically diverse tumor cells, and a heterogeneous TME. This complexity is rarely modeled&#xD;
      accurately in preclinical translational models of cancer. By utilizing intratumoral microdose&#xD;
      injections with CIVO in advance of scheduled surgical intervention, this study will evaluate&#xD;
      anti-cancer therapies directly in patients each with their own unique tumor genomic profile,&#xD;
      intact TME, and immune system functional status. Because the platform delivers microdose&#xD;
      amounts of each test agent or combination directly into the patient's tumor tissue,&#xD;
      hypotheses can be tested earlier in the drug development process, consistent with the goals&#xD;
      of the 2006 FDA Exploratory IND Guidance for Industry.&#xD;
&#xD;
      The CIVO device penetrates solid tumors and simultaneously delivers subtherapeutic microdoses&#xD;
      of up to eight anti-cancer agents or combinations of anti-cancer agents co-injected with CIVO&#xD;
      GLO into discrete regions of the tumor as drug columns. At the time of the planned surgical&#xD;
      intervention (at least four hours to up to seven days after the CIVO microdose injection),&#xD;
      the injected tumor tissue is then excised and tumor responses are assessed via histological&#xD;
      staining of tumor cross-sections sampled perpendicular to each injection column. Co-injection&#xD;
      with CIVO GLO enables identification of each injection site during resection as well as in&#xD;
      tissues stained for analysis. This Phase 0 Master Protocol is aimed at distinguishing&#xD;
      promising candidates earlier in the drug development process while also avoiding systemic&#xD;
      toxicities associated with typical clinical exposures to these therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">December 2031</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This Master Protocol is designed as an umbrella concept trial for the ongoing evaluation of multiple agents in individual CIVO Phase 0 substudies. Each substudy is considered an &quot;Experimental Arm&quot; with specified investigational agents and combinations to be evaluated. Comparisons will not be made between experimental arms.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of Cell Death and Immune Cell Biomarkers by IHC and In-Situ Hybridization</measure>
    <time_frame>4 hours-7 days after microdose injection</time_frame>
    <description>Quantification of biomarker-positive and biomarker-negative cells will be performed within the tumor microenvironment around each of the injection sites in each resected patient sample by IHC and ISH. An aggregate analysis of this quantification may be done across patient samples in each substudy to evaluate trends in tumor response. The biomarkers evaluated may include, but are not limited to biomarkers for cell death (e.g. cleaved caspase 3), T-cells (e.g. CD3, CD8/Granzyme B, CD4), natural killer (NK)/myeloid cells (e.g. CD56/Granzyme B, CD86, CD68, CD163), and proinflammatory cytokines (e.g., interferon gamma, tumor necrosis factor alpha, interferon gamma-induced protein 10).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>Up to 28 days after microdose injection</time_frame>
    <description>Relationship of AE to study drug(s) or CIVO device will be determined using an AE Relatedness Grading System.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HNSCC who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile dextrose) or subtherapeutic microdoses of BMS-986299, relatlimab, ipilimumab as single agents or combined with nivolumab. Each microdose is simultaneously injected in a columnar fashion through each of 8 or 5 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HNSCC who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-676, carboplatin, 5-fluorouracil (5-FU), or paclitaxel as single agents or in combination. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0482, MK-4830, &amp; Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HNSCC or STS who are scheduled for surgical biopsy or tumor resection surgery will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 8 needles into a single solid tumor or effaced metastatic lymph node.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986299</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
    <other_name>BMS-986016</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX-010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ipilimumab + Nivolumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Relatlimab + Nivolumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>BMS-986299 + Nivolumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>BMS-986299, Relatlimab, Ipilimumab, &amp; Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-676</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TAK-676 + Carboplatin</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Carboplatin + Paclitaxel</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Carboplatin + 5-FU</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TAK-676 + Carboplatin + 5-FU</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TAK-676 + Carboplatin + Paclitaxel</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>TAK-676, Carboplatin, 5-FU, &amp; Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>MK-0482, MK-4830, &amp; Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MK-0482 + Pembrolizumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>MK-0482, MK-4830, &amp; Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MK-4830 + Pembrolizumab</intervention_name>
    <description>Intratumoral microdose injection by the CIVO device.</description>
    <arm_group_label>MK-0482, MK-4830, &amp; Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        *This list is representative of study inclusion/exclusion criteria. Each substudy may&#xD;
        include variations on these criteria.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability and willingness to comply with the study's visit and assessment schedule.&#xD;
&#xD;
          2. Male or female â¥ 18 years of age at Visit 1 (Screening).&#xD;
&#xD;
          3. Pathologic diagnosis of [solid tumors] indicated in the relevant substudy(ies).&#xD;
&#xD;
          4. Ability and willingness to provide written informed consent. Voluntary written consent&#xD;
             must be given before performance of any study related procedure not part of standard&#xD;
             medical care, with the understanding that consent may be withdrawn by the patient at&#xD;
             any time without prejudice to future medical care.&#xD;
&#xD;
          5. At least one lesion (primary tumor, recurrent tumor, or effaced metastatic lymph node)&#xD;
             â¥ 2 cm in the shortest diameter that is surface accessible for CIVO injection that may&#xD;
             be guided by ultrasound if appropriate and for which there is a planned surgical&#xD;
             intervention. Treatment plan my include adjuvant radiation or chemotherapy and&#xD;
             patients should have no medical contraindication to surgery.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.&#xD;
&#xD;
          7. Female patients who:&#xD;
&#xD;
               -  Are postmenopausal for at least one year before the screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
               -  Are of childbearing potential who agree to practice a highly effective method of&#xD;
                  contraception from the time of signing the Informed Consent Form (ICF) and during&#xD;
                  study participation OR agree to completely abstain from heterosexual intercourse.&#xD;
&#xD;
               -  Agree to refrain from donating ova during study participation.&#xD;
&#xD;
        Male patients, even if surgically sterile (i.e., status post-vasectomy), who:&#xD;
&#xD;
          -  Agree to practice effective barrier contraception from the time of signing the ICF and&#xD;
             during study participation OR agree to completely abstain from heterosexual&#xD;
             intercourse.&#xD;
&#xD;
          -  Agree to refrain from donating sperm during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumors or effaced nodes that are anticipated by the Investigator to lack a sufficient&#xD;
             volume of viable tumor tissue (based on available pre-operative imaging, pre-injection&#xD;
             ultrasound imaging, or pathology reports) for CIVO injection due to size, location,&#xD;
             necrosis, cysts, excessive stroma, or fibrosis.&#xD;
&#xD;
          2. Patients who have received neoadjuvant therapy associated with the surgical&#xD;
             intervention described in Inclusion Criterion #5.&#xD;
&#xD;
          3. Tumors near or involving critical structures for which, in the opinion of the treating&#xD;
             clinician, injection would pose undue risk to the patient.&#xD;
&#xD;
          4. Female patients who are:&#xD;
&#xD;
               -  Both lactating and breastfeeding, OR&#xD;
&#xD;
               -  Have a positive Î²-subunit human chorionic gonadotropin (Î²-hCG) pregnancy test at&#xD;
                  screening verified by the Investigator.&#xD;
&#xD;
          5. Any uncontrolled intercurrent illness, condition, serious medical or psychiatric&#xD;
             illness, or circumstance that, in the opinion of the Investigator, could interfere&#xD;
             with adherence to the study's procedures or requirements, or otherwise compromise the&#xD;
             study's objectives.&#xD;
&#xD;
          6. Patients with a history of concurrent second cancers requiring active, ongoing&#xD;
             systemic treatment.&#xD;
&#xD;
          7. Patients with active autoimmune diseases requiring treatment.&#xD;
&#xD;
          8. Patients with known human immunodeficiency virus/acquired immune deficiency syndrome&#xD;
             (HIV/AIDS) with uncontrolled viral load and CD4 less than 200, or known chronic&#xD;
             hepatitis B/C.&#xD;
&#xD;
          9. Patients that have received a live vaccine within 4 weeks of the baseline/screening&#xD;
             visit.&#xD;
&#xD;
         10. Use of any of the following â¤ 2 weeks prior to CIVO injection:&#xD;
&#xD;
               1. Chronic systemic immunosuppressive therapy or corticosteroids (e.g., prednisone&#xD;
                  or equivalent exceeding a total dose of 140 mg over the last 14 days).&#xD;
                  Intranasal, inhaled, topical, or local corticosteroid injections (e.g.,&#xD;
                  intra-articular injection), or steroids as premedication for hypersensitivity&#xD;
                  reactions (e.g., computed tomography [CT] scan premedication) are exceptions to&#xD;
                  this criterion.&#xD;
&#xD;
               2. Biological response modifiers for treatment of active autoimmune disease.&#xD;
&#xD;
               3. Hematopoietic growth factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Presage Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Presage Biosciences</last_name>
    <phone>800-530-5404</phone>
    <email>clinops@presagebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LSU Health Sciences Center - Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gundle KR, Deutsch GB, Goodman HJ, Pollack SM, Thompson MJ, Davis JL, Lee MY, Ramirez DC, Kerwin W, Bertout JA, Grenley MO, Sottero KHW, Beirne E, Frazier J, Dey J, Ellison M, Klinghoffer RA, Maki RG. Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. Clin Cancer Res. 2020 Aug 1;26(15):3958-3968. doi: 10.1158/1078-0432.CCR-20-0614. Epub 2020 Apr 16.</citation>
    <PMID>32299817</PMID>
  </reference>
  <reference>
    <citation>Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, Dey J, Carleton M, Beirne E, Pedro KD, Ditzler SH, Girard EJ, Deckwerth TL, Bertout JA, Meleo KA, Filvaroff EH, Chopra R, Press OW, Olson JM. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci Transl Med. 2015 Apr 22;7(284):284ra58. doi: 10.1126/scitranslmed.aaa7489.</citation>
    <PMID>25904742</PMID>
  </reference>
  <reference>
    <citation>Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO, Beirne E, Watts KL, Keener A, Thirstrup DJ, Tretyak I, Ditzler SH, Tripp CD, Choy K, Gillings S, Breit MN, Meleo KA, Rizzo V, Herrera CL, Perry JA, Amaravadi RK, Olson JM, Klinghoffer RA. Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. Cancer Res. 2017 Jun 1;77(11):2869-2880. doi: 10.1158/0008-5472.CAN-17-0084. Epub 2017 Mar 31.</citation>
    <PMID>28364003</PMID>
  </reference>
  <reference>
    <citation>Dey J, Kerwin WS, Grenley MO, Casalini JR, Tretyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, Klinghoffer RA. A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. PLoS One. 2016 Jun 30;11(6):e0158617. doi: 10.1371/journal.pone.0158617. eCollection 2016.</citation>
    <PMID>27359113</PMID>
  </reference>
  <reference>
    <citation>Moreno-Gonzalez A, Olson JM, Klinghoffer RA. Predicting responses to chemotherapy in the context that matters - the patient. Mol Cell Oncol. 2015 Jun 10;3(1):e1057315. doi: 10.1080/23723556.2015.1057315. eCollection 2016 Jan.</citation>
    <PMID>27308571</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>lymphoma</keyword>
  <keyword>sarcoma</keyword>
  <keyword>breast adenocarcinoma</keyword>
  <keyword>melanoma</keyword>
  <keyword>intratumoral microdosing</keyword>
  <keyword>microdose injection</keyword>
  <keyword>microdosing</keyword>
  <keyword>in vivo oncology</keyword>
  <keyword>in vivo drug sensitivity</keyword>
  <keyword>tumor microenvironment</keyword>
  <keyword>multiplexed immunohistochemistry</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>pharmacodynamic biomarkers</keyword>
  <keyword>CIVO</keyword>
  <keyword>master protocol</keyword>
  <keyword>precision oncology</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

